Navigation Links
Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications
Date:7/28/2009

ion enhancements will be successful or will effectively simplify or expand the use of product candidates or technologies, that the GAM technology can be successfully broadened or applied to additional wound healing or tissue repair opportunities, that Excellarate or our other candidates will prove to be sufficiently safe and effective, that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures, that clinical studies even if successful will lead to product advancement or partnering, that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive, that FDA or other regulatory clearances or other certifications, or other commercialization efforts will be successful or will effectively enhance our businesses or their market value, that our products or product candidates will prove to be sufficiently safe and effective after introduction into a broader patient population, or that third parties on whom we depend will perform as anticipated.

Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to releas
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cardium Regains Listing Compliance with NYSE Amex
2. Cardiums InnerCool Therapies Business to Be Acquired By Royal Philips Electronics
3. Cardium Announces Conference Call and Webcast to Review Recent Developments and Future Plans for the Excellarate(TM) Clinical Development Program
4. FDA has Granted HUD (Humanitarian Use Device) Designation to ITGIs Pericardium Covered Stents, Over and Under(R) and Aneugraft(R), for Treatment of Perforations and Dissections of Native Coronary Arteries and Saphenous Vein Grafts
5. Cardium Completes $3.5 Million Credit Facility
6. Cardium Announces Retirement of Director
7. Cardiums InnerCool Announces First Patient Treated With New Tissue-Specific UroCool(TM) System in Robotic-Assisted Prostate Surgery Study
8. Cardiums InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries
9. Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units
10. Cardium Announces FDA 510(K) Clearance of InnerCools RapidBlue(TM) Endovascular System
11. ITGI Medical Received a CE Mark for its Second Pericardium Covered Stent - AneuGraft(R) - for Tortuous Vessels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... , Sept. 29, 2014  Atlas Venture, an early ... and technology innovation, today announced that Jason Rhodes ... EPZM ), is joining the firm,s life ... 2014. At Atlas, Rhodes will work closely ... He brings an accomplished record in company creation, deal ...
(Date:9/29/2014)... , September 29, 2014 ... greater competition to transform network connectivity as customers ... ProLabs , the leading independent ... today the findings of their survey conducted at ... with top optical communications professionals from across the ...
(Date:9/29/2014)... 2014 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that the U.S. ... Orphan Drug Designations for the Company,s lead drug ... small cell lung cancer and ovarian cancer.  Aldoxorubicin ... agent, doxorubicin. "The FDA,s decision to ...
(Date:9/28/2014)... Modality Solutions, a ... for highly regulated industries, is pleased to announce ... Advantage Transport Simulation Laboratoryâ„¢ software at the 12th ... Global Forum in Boston, September 29 through October ... lab software on October 2, day two of ...
Breaking Biology Technology:Atlas Venture Names Jason Rhodes, Veteran Investor and President and CFO of Epizyme, As Partner on Life Sciences Investing Team 2End of an Era: OEM Dominance - Could it be a Thing of the Past? 2CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 2CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 3CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 4CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 5Consulting Engineer Brian Brazill to Demonstrate Modality Solutions Advantage Transport Simulation Laboratory Software at 12th Annual Cold Chain Global Forum 2Consulting Engineer Brian Brazill to Demonstrate Modality Solutions Advantage Transport Simulation Laboratory Software at 12th Annual Cold Chain Global Forum 3
... terrorism scenarios that raise the most concern are ... reason, technology that can effectively detect smuggled radioactive ... To support the nation,s nuclear-surveillance capabilities, researchers at ... ways to enhance the radiation-detection devices used at ...
... 2012  Neogen Corporation (Nasdaq: NEOG ) announced today ... genomics business from Merial Limited. Igenity will operate as a ... place in the worldwide animal genomics business. ... several other countries for nine years, and already has provided ...
... (NASDAQ: SSRX ) ("3SBio" or "the Company"), ... manufacturing and marketing biopharmaceutical products, today announced that it ... for the fiscal year ended December 31, 2011 with ... 2012. The annual report on Form 20-F, which contains ...
Cached Biology Technology:Novel radiation surveillance technology could help thwart nuclear terrorism 2Novel radiation surveillance technology could help thwart nuclear terrorism 3Novel radiation surveillance technology could help thwart nuclear terrorism 4Neogen acquires Igenity from Merial 2Neogen acquires Igenity from Merial 3
(Date:9/29/2014)... found that a combination of a real-time feedback system ... of residence resulted in a reduction of 37% in ... were 1360.49 kWh, which is equivalent to a reduction ... weeks. , In contrast, another eight halls, exposed ... alert, resulted in saw a 3.5% reduction in energy ...
(Date:9/29/2014)... , Canda, September 29, 2014 ... Such as UID Coupled with Increasing Security Concerns ... India is one ... witnessing increasing adoption of biometrics systems, majorly in ... e-drivers, NREGA, etc. Fingerprint modality based biometrics dominates ...
(Date:9/29/2014)... Droplets are simple spheres of fluid, not normally considered ... researchers have made droplets of alcohol move through water. ... etc.,To be able to move on your own ... in living organisms. But also non-living entities can be ... Institute of Chemical Technology in Prague, Czech Republic. , ...
Breaking Biology News(10 mins):India Biometrics Market to Surpass USD2.7 Billion by 2019, Finds TechSci Research Study 2India Biometrics Market to Surpass USD2.7 Billion by 2019, Finds TechSci Research Study 3Scientists make droplets move on their own 2
... Dr. Zhihong Chen and colleagues from Chengde Medical ... Akt signaling, decrease heme oxygenase-1 expression in the ... of hippocampal neurons in diabetic rats, thus protecting ... the growth hormone/insulin-like growth factor 1 axis undergoes ...
... taken part in an international study which has discovered a ... of a region. And the secret lies in crushed ... been spent by researchers gathering, classifying and recording insects and ... region. Any changes to the biodiversity of that area could ...
... Control, Automation and Electrical Systems , a new journal in ... as Controle and Automao , the new journal will ... available on Springer,s online platform, SpringerLink . ... covers industrial automation, addressing such topics as circuits and systems; ...
Cached Biology News:Insect 'soup' serving up rapid biodiversity monitoring 2Journal of Control, Automation and Electrical Systems now published by Springer 2
Taq DNA polymerase, 10,000U...
... - 5 units/µL ,• High specific activity ... Leaves an 'A' overhang ,• Processes ... very high activity in primer extension and ... quality of the enzyme, each lot has ...
... a versatile and easy-to use enzyme, with ... Taq DNA Polymerase is prepared from a ... the DNA polymerase I gene from Thermococcus ... 5'-3' DNA polymerase activity. Its inherent 3'-5' ...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
Biology Products: